Progenics Pharmaceuticals, Inc. (PGNX)

Its basically cash rich, has a few good products waiting to be launched once a partner is found for marketing, and its current stock price is an all time low, which can't get any worse than this.

can you say money pit!

Current 5.78, Sept 18 09. Limit 5.55

Great

I feel that this stock has stabilized. At such a low price, and with an approved drug, PGNX is an attractive acquisition. The pipeline is nice, but competes with more exciting candidates.

EXCELLENT PIPELINE, NO DEBT, GOOD MANAGEMENT

biotech. purchased pgnx in real life portfolio today @6.60/share

Your leader returns to his adoring subjects. Subcu MNTX is approved and has clocked some initial sales, which are at a level I would describe as encouraging. While Progenics won't become profitable based on this, it gives them some cushion as they develop the oral form of the drug and work on their other longshot projects, such as Pro140 for HIV. In the meantime having a marketed compound makes them a potential buyout candidate for Wyeth. I'm looking for a rebound to the 15 range as the market sphincter relaxes.

Down on no news - owned this through FDA and EMEA approvals but then sold out - back now since it's at the same levels again but closer to profitability and/or buyout (Wyeth?)

Sales of Relistor are just starting in the US for terminal patients with advanced medical illness. Their partner Wyeth has a large sales force ramped up and ready to go. Sales will likely be far greater than intitial estimates due to a higher price and significant off label usage. Approval will be granted in Europe and Australia later this year. PGNX could still earn about $300 million in milestone payments from Wyeth from Relistor, assuiomg it getst approved for chroinic pain. Their anti-HIV antibody, which blocks HIV entiry via the CCR5 receptor, should generate excellent results in two phase II trials. These trials are in progress and will be completed by year's end or early 2009. PRO140 is still fully owned by PGNX so partnership dollars could roll in next year.

has found a firm base will retest mid to high twentys by end of fall

With people living longer and longer, new technologies are needed to assure quality products are in place to facilitate that trend.

I think this company has a brigth future.

This company has always caught my eye, and never knew when the right time was to invest. They are surely paying off now...

This company is all about developing innovative products to help unmet medical needs of patients with debilitating conditions and life-threatening diseases. This company, as I see, will be, in the MONEY!

This stock will blow your socks off!

pharmaceuticals never lose

Progenics said early Tuesday it and marketing partner Wyeth received approval from Canadian regulators to sell the methylnaltrexone injection, which treats constipation induced by opiate pain medications, such as morphine, in patients with advanced illnesses for whom laxatives have been ineffective.

Progenics and Wyeth said Relistor is the first approved therapy in a new class of drugs designed to relieve opiod-induced constipation without interfering with pain relief. The product is expected to be available to patients in Canada within about 60 days.

Partnership with Wyeth. Awaiting possible NDA approval for OIC drug currently under review by FDA. Their competitor Adolor/GSK saw saftey risks in their long term safety studies and will be going to an AdCom January 23.

Formulation and indication not ideal for huge market share, but have plans for i.v. and oral formulations in POI and chronic pain indications, which are larger markets.